JOINN Laboratories (China) Co., Ltd. has released an unaudited earnings preview for 1 January–30 June 2026, signalling a sharp turnaround in profitability mainly attributable to fair-value gains on biological assets.

Revenue Outlook • Expected revenue: RMB668.63 million–RMB739.01 million, implying year-on-year growth of 0.0%–10.5% versus RMB668.58 million in the prior-year period. • Management cited only a “slight” increase in laboratory services revenue amid continued industry competition.

Profit Projection • Net profit attributable to shareholders is forecast at RMB600.13 million–RMB900.19 million, up 884.9%–1,377.4% from RMB60.93 million a year earlier. • After excluding non-recurring items, underlying net profit is expected at RMB561.14 million–RMB841.71 million, a surge of 2,334.2%–3,551.3% compared with RMB23.05 million in H1 2025.

Segment Contribution • Changes in the fair value of biological assets are projected to add RMB702.77 million–RMB776.74 million to net profit. • Core laboratory services and other businesses are expected to report net profit between a loss of RMB141.62 million and a profit of RMB64.97 million, versus a loss of RMB64.80 million in the comparable period.

Management Commentary The Board attributes the exceptional profit growth primarily to rising market prices and organic appreciation of biological assets. In contrast, while laboratory operations remained “stable and sound,” competitive pressures limited revenue expansion and weighed on gross margins.

Audit Status and Timeline The figures are based on unaudited management accounts. Final interim results for H1 2026 are slated for release by end-August 2026. Shareholders and potential investors are advised to interpret the estimates with caution pending audited financials.